Company news
TScan Therapeutics, Inc. news in 2023
TScan Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition
December 8, 2023
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations
December 6, 2023
TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer
December 3, 2023
TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 8, 2023
TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition
November 1, 2023
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME
August 28, 2023
TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 9, 2023
TScan Therapeutics Announces Transition of Chief Financial Officer
June 28, 2023
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors
June 5, 2023
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting
May 31, 2023
TScan Therapeutics Announces Pricing of $140 Million Public Offering
May 25, 2023
TScan Therapeutics Announces Launch of Proposed Public Offering
May 24, 2023
TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors
May 23, 2023
TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting
May 16, 2023
TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 9, 2023
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting
May 1, 2023
TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors
April 9, 2023
TScan Therapeutics Announces CEO Transition
March 30, 2023
TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies
March 13, 2023
TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones
March 7, 2023
TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference
February 20, 2023
TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors
January 22, 2023
TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress
January 4, 2023
Decks in 2023
- Technical Presentation (December 2023)
Technical · 29 slides · Dec 11, 2023
- Investor Presentation (June 2023)
Investor deck · 61 slides · June 2023